MesenFlow Technologies

Commentary on the paper in Nature Comms, with the founders of MesenFlow. Applying translational technologies to cancer therapy.

Cutting off tumor supplies: By discovering two elements essential to the vascularization of tumors, and thus to their survival, scientists are taking a step forward towards more effective cancer therapies For a tumour to grow, it must develop blood vessels that supply nutrients and oxygen. Preventing tumor vascularization is therefore an interesting anti-tumor therapy that has been explored over the last ten years. But how to be truly effective? By identifying two cytokines, key factors in the recrui...

Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French).

Couper les vivres aux tumeurs - Radio - Play RTS Comment priver de manière ciblée les cellules cancéreuses de leur nourriture et de leur oxygène? C'est l'objet d'une recherche menée à l'Université de Genève (Unige). Les explications d'Adama Sidibé, chercheur au Département de physiologie et métabolisme cellulaire du Centre médical univ...

Translational medicine in action, and a validation of the MesenFlow approach.
Mesechymal factors play a key role in regulating human monocyte function, in chronic inflammation and cancer.

Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours Circulating myeloid cells can leave the vasculature to infiltrate tumours and are thought to contribute to tumour angiogenesis. Here the authors live image monocytes that migrate to xenograft tumours and map an extravasation cascade of human proangiogenic monocytes into the tumour.

CPhI Worldwide 2017 I have just registered for this. Are you coming too?